We collected RNA-sequencing data from pre-treatment biopsies derived from NeoALTTO, a trial randomizing pts with HER2+ early BC to receive lapatinib, trastuzumab or both together with weekly paclitaxel....Overall, pCR rate was significantly higher in pts with RBsig High tumors, than those with RBsig Low (36% vs 18% respectively p = 0.01)….RBsig Low expression identifies a subset of HER2+ pts less likely to respond to CT + H.